Results 81 to 90 of about 69,829 (275)

Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study

Antimicrobial Agents and Chemotherapy, 2019
The use of antifungal agents in clinical settings is limited by the appearance of drug resistance and adverse side effects. There is, therefore, an urgent need to develop new drugs to strengthen the treatment of invasive fungal diseases.
H. Yousfi, C. Cassagne, S. Ranque, J. Rolain, F. Bittar   +4 more
semanticscholar   +1 more source

Exploring Therapeutic Targets From Spreading Patterns Against Respiratory Syncytial Virus

The FASEB Journal, Volume 39, Issue 14, 31 July 2025.
RSV spreads through three main modes of infection: receptor‐dependent infection of free viral particles, syncytia formation, and transmission via actin filaments. CX3CR1, CCR3, and HSPG mediate viral adsorption; the IGF1R signaling pathway facilitates viral internalization by recruiting NCL to the membrane surface, and the RHO GTPase and PI3K signaling
Han Zhang, Zhao Zhang, Yixuan Yang, Jingjing Pei   +3 more
wiley   +1 more source

Addressing the Health Risks Posed by Adenovirus: A Perspective on Strategies for Prevention and Management

Health Science Reports, Volume 8, Issue 7, July 2025.
ABSTRACT Background Adenovirus (AdV) is a non‐enveloped virus with a double‐stranded DNA genome that can infect the respiratory and gastrointestinal tracts, as well as cause conjunctivitis. The infection is influenced by the patient's age, environment, temperature, and immunocompromised individuals.
Taslima Jamal Urmi, Jannatul Mabia Rahman, Syed Masudur Rahman Dewan   +2 more
wiley   +1 more source

Ribavirin as a beneficial treatment option for hepatitis C virusassociated glomerular disease

Saudi Journal of Kidney Diseases and Transplantation, 2020
The management of hepatitis C virus (HCV)-induced glomerular disease remains unsatisfactory despite novel advances in antiviral and immunosuppressive therapy.
Fabrizio Fabrizi, Donata Cresseri, Gabriella Moroni, Patrizia Passerini, Francesco Pallotti, Francesca Maria Donato, Pietro Lampertico, Piergiorgio Messa   +7 more
doaj   +1 more source

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

Gastroenterology, 2002
BACKGROUND & AIMS Liver fibrosis is an important prognostic factor in patients with hepatitis C. The effect of pegylated (PEG) interferon alone or its combination with ribavirin on fibrosis has not been established.
T. Poynard, J. Mchutchison, M. Manns, C. Trépo, K. Lindsay, Z. Goodman, M. Ling, J. Albrecht   +7 more
semanticscholar   +1 more source

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, Volume 170, Issue 1, Page 28-48, July 2025.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin

Viruses, 2012
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C.
Osamu Yokosuka, Fumio Imazeki, Makoto Arai, Keiichi Fujiwara, Xia Jiang, Shuang Wu, Shingo Nakamoto, Tatsuo Kanda, Tatsuo Miyamura   +8 more
doaj   +1 more source

Sofosbuvir Add-on to Ribavirin Treatment for Chronic Hepatitis E Virus Infection in Solid Organ Transplant Recipients Does Not Result in Sustained Virological Response

Open Forum Infectious Diseases, 2019
Ribavirin is effective for treating immunocompromised patients with chronic hepatitis E virus infection. However, ribavirin treatment is not always successful.
E. M. V. Wezel, J. J. D. Bruijne, K. Damman, M. Bijmolen, A. P. V. D. Berg, E. A. Verschuuren, G. Ruigrok, A. Riezebos-Brilman, M. Knoester   +8 more
semanticscholar   +1 more source

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome

Gut, 2016
Objective Hepatitis E virus (HEV) infection can take chronic courses in immunocompromised patients potentially leading to liver cirrhosis and liver failure.
D. Todt, A. Gisa, A. Radonic, A. Nitsche, P. Behrendt, P. Suneetha, S. Pischke, B. Bremer, Richard J. P. Brown, Michael P. Manns, Michael P. Manns, M. Cornberg, M. Cornberg, C. Bock, E. Steinmann, H. Wedemeyer, H. Wedemeyer   +16 more
semanticscholar   +1 more source

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt

Gut, 2018
Objective We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were infected with hepatitis C virus (HCV) genotype 4, including those who had failed
G. Shiha, G. Esmat, M. Hassany, R. Soliman, M. Elbasiony, Rabab Fouad, A. Elsharkawy, Radi Hammad, W. Abdel-Razek, Talaat Zakareya, K. Kersey, B. Massetto, A. Osinusi, Sophia Lu, D. Brainard, J. Mchutchison, I. Waked, W. Doss   +17 more
semanticscholar   +1 more source